News
![Tender offer for hybrid capital securities – final results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Tender offer for hybrid capital securities – final results
![E15VC Announces First Close of its Third Fund with the Continued Support from Sun Hung Kai & Co](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
E15VC Announces First Close of its Third Fund with the Continued Support from Sun Hung Kai & Co
![EQS-News: Elmos Semiconductor SE to be included in the SDAX](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
EQS-News: Elmos Semiconductor SE to be included in the SDAX
![Arix to Present at Mello Investment Trusts & Funds](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Arix to Present at Mello Investment Trusts & Funds
![EQS-News: Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
EQS-News: Defence Therapeutics Inc.: DEFENCE POSITIONED TO BEGIN ITS ANTI-CANCER ACCUTOXTM PHASE I TRIAL WITH SUCCESSFUL COMPLETION OF GLP STUDIES
![Schaffner Group delivers successful fiscal 2021/22](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Schaffner Group delivers successful fiscal 2021/22
![Arbonia continues to strengthen HVAC sales position in Spain and Portugal](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Arbonia continues to strengthen HVAC sales position in Spain and Portugal
![Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
![Investor Day for knowledge transfer and information about TX Group’s strategic direction](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Investor Day for knowledge transfer and information about TX Group’s strategic direction
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=us)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Pershing Square Holdings, Ltd. Releases Date of Annual London Investor Presentation: https://mms.businesswire.com/media/20210511006122/en/713603/5/pershing-square-holdings.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNDZFVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a5ff17c971a04533f564f99c5336e36dec36320f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pershing-square-holdings.jpg?locale=us)
Pershing Square Holdings, Ltd. Releases Date of Annual London Investor Presentation
Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (NA:PSH) (the “Company”) today announced that it will hold its annual PSH Investor Presentation on 9 February 2023 at 15:00 GMT (10:00 EST).
Any
![Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=us)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
UBS Advisor Team FTB Financial Services Named to the Forbes America’s Top Wealth Management Teams list
UBS Wealth Management USA announced today that FTB Financial Services, a wealth management team in the firm’s Kenwood, Ohio branch has been named to the Forbes America’s Top Wealth Management Teams
American Express Relaunches Leadership Academy in Partnership With Common Purpose, TED Foundation, and Taproot Foundation
American Express (NYSE: AXP) today announced the return of its American Express Leadership Academy, with a new curriculum to help nonprofit leaders innovate and meet the rapidly-changing needs of
![Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke: https://mms.businesswire.com/media/20220330005534/en/1304115/5/Acticor_Biotech.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0E1V0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--88f66b14b363ef5936f06d96faa19414e4bfd6e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Acticor_Biotech.jpg?locale=us)
Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke
Regulatory News:
Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of
![NTT DATA Named a Top Employer for LGBTQ+ Inclusion in India and Mexico: https://mms.businesswire.com/media/20200901005792/en/817545/5/NTT-DATA-Logo-HumanBlue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM004VEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--01ff047525fbd8ebf640fa202f634ab3d2d0587a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NTT-DATA-Logo-HumanBlue.jpg?locale=us)
NTT DATA Named a Top Employer for LGBTQ+ Inclusion in India and Mexico
NTT DATA, a global digital business and IT services leader, announced today it has been named a 2022 Top Employer by the India Workplace Equality Index (IWEI) and an LGBTQ+ 2023 Best Place to Work
![Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
![Fuller, Smith & Turner PLC: Transaction in Own Shares](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Fuller, Smith & Turner PLC: Transaction in Own Shares
![GEVELOT S.A.: Weekly report of share buyback December 5, 2022](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
GEVELOT S.A.: Weekly report of share buyback December 5, 2022
![Rights and Issues Investment Trust PLC: Transaction in Own Shares](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Rights and Issues Investment Trust PLC: Transaction in Own Shares
![Chelverton UK Dividend Trust plc: Net Asset Value(s) - REPLACEMENT](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Chelverton UK Dividend Trust plc: Net Asset Value(s) - REPLACEMENT
![Eurofins Launches BQ.1 and BQ.1.1 Droplet Digital PCR Assay (ddPCR) for SARS-CoV-2 Wastewater Testing: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=us)
Eurofins Launches BQ.1 and BQ.1.1 Droplet Digital PCR Assay (ddPCR) for SARS-CoV-2 Wastewater Testing
Eurofins Environment Testing Northern California: Wastewater (EWW) and Eurofins Pandemic Prevention Services (EPPS) today launched a droplet digital PCR (ddPCR) assay for the combined quantitative
![Director/PDMR Shareholding](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Director/PDMR Shareholding
![Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=us)
Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare
Humana Inc. (NYSE: HUM) is proud to announce that Bruce D. Broussard, President and Chief Executive Officer, is recognized by Modern Healthcare as one of the 100 Most Influential People in
![Groupon to Participate in the Barclays Global Technology, Media & Telecommunications Conference: https://mms.businesswire.com/media/20191104006028/en/466257/5/wordmark_one_cmyk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0VtRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3fb5f17eb6e7fc45ed529f622686a2dfd22a6050/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/wordmark_one_cmyk.jpg?locale=us)
Groupon to Participate in the Barclays Global Technology, Media & Telecommunications Conference
Groupon, Inc. (NASDAQ: GRPN) announced that Kedar Deshpande, Chief Executive Officer, and Damien Schmitz, Chief Financial Officer, will participate in the Barclays Global Technology, Media &